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SUMMARY
We undertook a 5-year retrospective study of group A streptococcal (GAS) bacteraemia in Fiji,
supplemented by a 9-month detailed retrospective study of b-haemolytic streptococcal (BHS)
infections. The all-age incidence of GAS bacteraemia over 5 years was 11.6/100 000. Indigenous
Fijians were 4.7 times more likely to present with invasive BHS disease than people of other
ethnicities, and 6.4 times more likely than Indo-Fijians. The case-fatality rate for invasive BHS
infections was 28%. emm-typing was performed on 23 isolates : 17 diﬀerent emm-types were
found, and the emm-type proﬁle was diﬀerent from that found in industrialized nations. These
data support the contentions that elevated rates of invasive BHS and GAS infections are
widespread in developing countries, and that the proﬁle of invasive organisms in these settings
reﬂects a wide diversity of emm-types and a paucity of types typically found in industrialized
countries.
INTRODUCTION
Recent studies have identiﬁed an increasing incidence
of invasive group A streptococcal (GAS) infections
worldwide [1, 2] ; there has also been a growing num-
ber of reports of invasive disease caused by Lanceﬁeld
group C and group G streptococci (GCS and GGS),
also known as Streptococcus dysgalactiae subsp.
Equisimilis [3, 4]. The incidence of invasive GAS
infections in industrialized nations from well-
established population-based studies ranges from 1.9
to 3.8/100 000 with a case-fatality rate of 10–13%
[5–7]. However, the epidemiological picture is not
clear in less-developed nations. From the limited
published data available it is probable that invasive
GAS disease is more common in these regions [8]. For
example, in a recent study in Kenya, the incidence of
GAS bacteraemia in children aged <1 year was 96/
100 000 and in children aged<15 years the incidence
was 13/100 000 [9]. Studies in indigenous populations
in otherwise wealthy nations have also shown a high
incidence of invasive GAS disease; 82/100 000 in
Australian Aboriginals in Queensland and 46/100 000
in Native Americans in Arizona [10, 11].
The most common clinical presentation of invasive
GAS infection is soft-tissue infection, including
necrotizing fasciitis. Other presentations include
pneumonia, septic arthritis and bacteraemia without
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focus. Invasive GAS infection is complicated by the
development of streptococcal toxic shock syndrome
in about 10% of cases [12]. The clinical presentation
of invasive GCS and GGS disease appears to be
similar to invasive GAS disease and toxic shock syn-
drome can also occur [13].
The molecular epidemiology of invasive GAS
disease has been carefully recorded in some in-
dustrialized nations over the past several years par-
ticularly under the auspices of strep-EURO in Europe
and the Centers for Disease Control and Prevention
in the United States [1, 5, 14]. These surveillance
systems have identiﬁed a wide variety of emm-types
but with a clear predominance for a smaller number
of dominant emm-types including emm-types 1, 3, 12
and 28 [5]. In contrast, available molecular data from
indigenous populations such as the Aboriginal popu-
lation in Northern Queensland and the Northern
Territory of Australia demonstrate no apparent
dominant emm-types [11, 15].
There are no published data on the incidence of
invasive BHS or GAS infections in Paciﬁc Island
Countries, where there is a demonstrated high burden
of other GAS diseases such as rheumatic fever and
post-streptococcal glomerulonephritis [16, 17]. We
aimed to document the epidemiology of invasive
b-haemolytic streptococcal (BHS) infections in a
developing country in the Paciﬁc.
Setting
Fiji is an independent republic of some 300 islands in
the Western Paciﬁc north of the Tropic of Capricorn.
It has an estimated current population of 832 000
people comprising of two major racial groups of
Indigenous Fijians (over 50%) and Indo-Fijians
(y40%). Fiji is ranked 90 out of 177 nations on the
United Nations Development Programme Human
Development Index and has a GDP per capita of
US$ 6066 and an infant mortality rate of 16/1000 [18].
The overall crude mortality rate in Fiji is 5.3/1000,
and life expectancy at birth is 64.5 years for males
and 68.7 years for females [19]. More than 53% of
the population live in rural areas. The major hospital,
the Colonial War Memorial Hospital (CWMH), is
located in the capital, Suva, in the Central Division of
Fiji, on the main island of Viti Levu. This hospital
predominantly serves the Central Division of Fiji,
although patients from other divisions of Fiji may be
referred to the hospital. We used the population of
the Central Division from the most recent complete
census in 1996 as the denominator for incidence cal-
culations ; the total population of the Central Division
at this time was 297 607 with 175 878 being Indigenous
Fijian (59.1%) and 98 660 being Indo-Fijian (33.2%).
METHODS
We performed a retrospective review of positive GAS
blood cultures at CWMH from people living in the
Central Division during the period January 2000 to
February 2005. GAS isolates and detailed clinical
data were not available for most of these cases, so we
supplemented these data with a more comprehensive
review of cases of sterile site (blood culture, CSF and
sterile site aspirates) BHS isolates during the 9-month
period from June 2004 to February 2005. Clinical
and demographic data were collected from the hos-
pital electronic database and where available medical
charts were reviewed for clinical information. In
almost half of the cases the corresponding sterile site
isolates were available for emm-typing, which was
performed using the current technique devised by the
Centers for Disease Control and Prevention (CDC,
Atlanta, GA, USA) [20]. In addition, these isolates
were all tested for the presence of conserved epitopes
in the C-repeat region of the M protein, as described
previously [21, 22]. Relative risks were calculated as
incidence rate ratios with 95% conﬁdence intervals
(95% CI). This work was approved by the Fiji
National Research Ethics Review Committee.
RESULTS
GAS bacteraemia, 2000–2005
The annual all-age incidence of positive GAS blood
cultures in the Central Division for the 5-year period
Table 1. Group A streptococcal bacteraemia in the
Central Division of Fiji, January 2000 to February
2005
Age group
(years)
No. of
cases Population
Annual incidence
per 100 000
(95% CI)
0–4 48 35 759 26 (19.2–34.4)
5–14 3 65 890 0.9 (0.2–2.6)
15–34 13 109 966 2.3 (1.2–3.9)
35–64 64 76 880 16.1 (12.4–20.6)
>64 40 9112 85 (60.7–115.7)
Unknown 11 — —
Total 179 297 607 11.6 (10–13.5)
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January 2000 to February 2005 was 11.6/100 000
(95% CI 10.0–13.5), with the highest rates in children
(<5 years) and the elderly (>64 years, Table 1).
There were no seasonal peaks observed.
Invasive BHS infections, 2004–2005
During the 9-month period there were 49 cases of
invasive BHS disease (39 GAS, 6 GGS and 4 GCS,
Tables 2 and 3). Thirty-nine of these occurred in
residents of the Central Division (all-age annual
incidence of invasive BHS disease 17.5/100 000,
95%CI 12.4–23.9; Table 3). Thirty-one cases of
invasive GAS infection occurred in residents of the
Central Division (all-age incidence 13.9/100 000,
95% CI 9.4–19.7), similar to the incidence for the
2000–2005 period). The age distribution paralleled
the bimodal distribution seen in the 2000–2005
period, with peaks occurring in children aged <5
years (44.7/100 000, 95% CI 23.1–78.2) and adults
aged>64 years (146.3/100 000, 95% CI 70.2–269).
Ethnicity data were available in 48 cases, of which
42 (88%) were Indigenous Fijians. The incidence rate
ratio for invasive BHS infections in the Central
Division in Indigenous Fijians was 4.7 (95% CI
1.8–15.4) compared to other races, and 6.4 (95%
CI 2.0–32.4) compared to Indo-Fijians (Table 3).
Of the 43 cases of invasive BHS disease with out-
come information available there were 12 deaths
(case-fatality rate 28%). Two of these occurred in
children aged<5 years of age. Of the 34 cases of GAS
disease with outcome information available there
were 10 deaths (case-fatality rate 29%).
BHS were isolated from blood culture alone in 43
cases, from joint aspirate alone in four cases, from
both blood culture and joint aspirate in one case, and
from CSF in one case. We were able to ascertain a
clinical diagnosis in 42 of these 49 cases. Soft-tissue
infections were the most common clinical infection
(12 cases, 29%), followed by pneumonia (10, 24%),
and septic arthritis (8, 19%). Meningitis occurred in
three patients. Accurate data to assess the proportion
of cases complicated by streptococcal toxic shock
syndrome were not available. The only reliable risk
factor data were for diabetes and pyoderma. Of the 22
cases of BHS disease with risk factor information
available, 10 (45%) had co-existing diabetes and eight
(36%) had had pyoderma in the preceding 28 days.
Twenty-three BHS isolates were available for emm-
typing. There were 17 diﬀerent emm-types, including
12 diﬀerent emm-types among the 16 GAS isolates.
There were four cases with emm-type STN5554,
three cases with emm-type STC74A and two cases
with emm-type 18, otherwise all other cases were
unique emm-types. STC74A was shared between
GCS and GGS cases. emm-subtype 12.8, normally
associated with GAS, was seen in a GGS isolate. All
23 isolates tested contained a conserved region
epitope that is recognized by antisera to the vaccine
candidate J8.
DISCUSSION
These data conﬁrm that invasive BHS and GAS
infections occur at elevated rates in Fiji compared to
industrialized countries, and suggest that previous
ﬁndings of high rates in Kenya and indigenous
populations of Australia and the United States may
reﬂect a general tendency for these diseases to occur
more frequently in developing countries. Together
with the high case-fatality rate documented here,
this study supports our previous contention that the
global burden of invasive GAS infections has been
considerably underestimated [8].
We found a signiﬁcantly elevated rate of invasive
BHS infections in the Indigenous Fijian population
compared with people of other racial backgrounds
in Fiji. We did not have suﬃcient data to determine
if this reﬂects an ethnic susceptibility or other
factors (e.g. increased exposure to organisms because
of overcrowded living conditions). Other studies
have found higher rates of bacterial infections in
Indigenous Fijians: one study found that Indigenous
Fijian children were 29 times more likely than
Indo-Fijian to present with chest X-ray-conﬁrmed
pneumonia [23]. It is our observation that the socio-
economic status of Indigenous Fijians is not signiﬁ-
cantly worse than Indo-Fijians; a survey of household
income and expenditure in 2002 found that 29.7% of
Indigenous Fijian adults and 33.4% of Indo-Fijian
adults were in full-time employment [24]. This raises
the possibility that Indigenous Fijians may have an
increased susceptibility to particular infections and
this deserves further study.
The case-fatality rate in this study for invasive
BHS and GAS infections was higher than in in-
dustrialized nations. Whilst this high rate probably
represents late presentation and reduced availability
of medical care such as access to intensive care
and intravenous immunoglobulin, even under ideal
conditions a substantial proportion of cases can be
expected to die.
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Table 2. Detail of cases of b-haemolytic streptococcal (BHS) invasive disease at the Colonial War Memorial Hospital June 2004 to February 2005, by
Lanceﬁeld group and by age
Patient no.
BHS
group Age Gender Ethnicity
Clinical
infection
Risk
factors
Residence
by division
Culture
site Outcome emm-subtype
1 A 2 mo. F Indo-Fijian Sepsis n.a. Central BC Deceased 68
2 A 2 mo. F Fijian Pneumonia n.a. Central BC Recovered n.a.
3 A 2 mo. M Fijian Sepsis n.a. Central BC Recovered n.a.
4 A 3 mo. F Fijian Skin sepsis Pyoderma* Central BC Recovered n.a.
5 A 5 mo. F Fijian Sepsis n.a. Central BC Recovered n.a.
6 A 7 mo. F Fijian Meningitis n.a. Central CSF Recovered n.a.
7 A 8 mo. F Fijian Pneumonia Pyoderma* Central BC Recovered 81.3
8 A 10 mo. F Fijian n.a. n.a. Northern BC n.a. n.a.
9 A 1 yr 3 mo. M Fijian Pneumonia n.a. Central BC Recovered n.a.
10 A 1 yr 9 mo. M Indo-Fijian Sepsis No risk factor identiﬁed Central BC Recovered 25
11 A 2 yr 1 mo. M Fijian Meningitis n.a. Central BC Deceased STN5554
12 A 2 yr 10 mo. F Fijian Septic arthritis Pyoderma* Central Joint aspirate Recovered 18.12
13 A 4 M Fijian Meningitis n.a. Northern BC n.a. n.a.
14 A 24 F Fijian Gynaecological n.a. Eastern BC Recovered n.a.
15 A 25 M Fijian Endocarditis n.a. Central BC Recovered n.a.
16 A 27 M Fijian Septic arthritis n.a. Central Joint aspirate Recovered n.a.
17 A 32 M Fijian Pyomyositis/septic
arthritis
n.a. Central Joint aspirate Recovered n.a.
18 A 36 F Fijian Cellulitis Diabetes Central BC Recovered 18.2
19 A 42 M Fijian Septic arthritis n.a. Eastern Joint aspirate Recovered n.a.
20 A 43 M Other Peritonitis n.a. Central BC Deceased n.a.
21 A 52 M Fijian n.a. n.a. Central BC Recovered n.a.
22 A 54 F Fijian Soft tissue Diabetes/Pyoderma* Central BC Amputation 104
23 A 54 F Fijian Sepsis Diabetes Central BC Deceased n.a.
24 A 55 F Fijian Neck abscess Diabetes Central BC Deceased 116.1
25 A 58 F Fijian Wound infection Diabetes Central BC Deceased STN5554.1
26 A 58 M Fijian Pneumonia n.a. Central BC Recovered n.a.
27 A 59 F Fijian n.a. n.a. Central BC Recovered n.a.
28 A 60 F Fijian Soft tissue Diabetes Eastern BC Recovered 22.1
29 A 60 M Other Chest abscess Diabetes/Pyoderma* Central BC Deceased 86.2
30 A 65 M Fijian Wound infection Diabetes/Pyoderma* Central BC Recovered 74
31 A 66 F Fijian Leg abscess Pyoderma* Central BC Deceased 4.5
32 A 67 F Indo-Fijian Cellulitis n.a. Central BC Deceased n.a.
33 A 68 F Fijian Cellulitis n.a. Northern BC n.a. n.a.
34 A 71 F Fijian Sepsis Diabetes/Pyoderma* Central BC Recovered n.a.
35 A 73 F Fijian Septic arthritis No risk factor identiﬁed Central BC Recovered STN5554.1
36 A 79 M Fijian Pneumonia Diabetes Central BC Deceased 71
37 A 83 M Fijian Pneumonia n.a. Central BC Recovered n.a.
38 A n.a. n.a. n.a. n.a. n.a. n.a. BC n.a. STN5554.1
39 A n.a. F Fijian n.a. n.a. Northern BC n.a. n.a.
40 G 3 yr 6 mo. F Fijian Pneumonia No risk factor identiﬁed Central BC Recovered STC74A
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The ﬁndings in this study of a high number of in-
vasive skin infections and the apparent association of
pyoderma with invasive disease suggests a potential
role for skin sore and scabies control programmes in
reducing invasive disease incidence. The ﬁndings also
support the need to consider prevention of pyoderma
as well as pharyngitis in the development of GAS
vaccines.
Although the number of isolates that were emm-
typed in this study was small, there was relatively
high genetic diversity, with 17 diﬀerent emm-types
among the 23 isolates from invasive BHS infections
and 12 diﬀerent emm-types among the 16 isolates
from invasive GAS infections. In recent surveillance
studies of invasive GAS isolates in the United States,
only 41 emm-types were found among 1064 isolates
[14]. In addition to this comparatively higher genetic
diversity of emm-types, the emm-types recovered
from the isolates in this study were diﬀerent to those
found in the United States. This mirrors the ﬁndings
for both invasive and non-invasive GAS isolates in
other tropical areas, including in Hawaii and in
Aboriginal populations in northern Australia, and in
other developing countries [11, 25, 26]. These ﬁnd-
ings have implications for the development of a GAS
vaccine. There are a number of GAS vaccine candi-
dates currently under development but only one
vaccine has reached clinical trials – this vaccine is a
multivalent vaccine containing N-terminal protein
fragments from 26 common serotypes of GAS from
the United States [27]. In our study only two of the
17 diﬀerent emm-types found are included in this
vaccine (emm-type 18 and emm-type 22). A vaccine
based upon the conserved region of the M protein
may circumvent this problem of serotype speciﬁcity.
An epitope, J8, has been identiﬁed in the conserved
C-repeat portion of the M protein and is the subject
of vaccine research [22] ; in our study all GAS, GCS
and GGS isolates tested contained a conserved re-
gion epitope that is recognized by antisera to the J8
vaccine candidate.
The epidemiology of invasive GAS infections and
other invasive BHS infections is poorly understood
in most developing nations. The data from this study
represent the beginning of more detailed epidemi-
ological research in Fiji and indicate that invasive
GAS disease is more common in Fiji than in in-
dustrialized nations and that the case-fatality rate is
high. This study also indicates that emm-type proﬁle
is diﬀerent from industrialized nations, but appears
similar to the Aboriginal population in northernT
a
b
le
2
(c
o
n
t.
)
P
a
ti
en
t
n
o
.
B
H
S
g
ro
u
p
A
g
e
G
en
d
er
E
th
n
ic
it
y
C
li
n
ic
a
l
in
fe
ct
io
n
R
is
k
fa
ct
o
rs
R
es
id
en
ce
b
y
d
iv
is
io
n
C
u
lt
u
re
si
te
O
u
tc
o
m
e
em
m
-s
u
b
ty
p
e
4
1
G
3
7
M
F
ij
ia
n
S
ep
si
s
N
o
ri
sk
fa
ct
o
r
id
en
ti
ﬁ
ed
C
en
tr
a
l
B
C
R
ec
o
v
er
ed
S
T
C
3
6
4
2
G
5
6
M
In
d
o
-F
ij
ia
n
S
ep
ti
c
a
rt
h
ri
ti
s
n
.a
.
n
.a
.
B
C
n
.a
.
n
.a
.
4
3
G
5
7
M
F
ij
ia
n
P
n
eu
m
o
n
ia
N
o
ri
sk
fa
ct
o
r
id
en
ti
ﬁ
ed
C
en
tr
a
l
B
C
R
ec
o
v
er
ed
S
T
G
4
8
0
4
4
G
6
8
M
F
ij
ia
n
P
n
eu
m
o
n
ia
N
o
ri
sk
fa
ct
o
r
id
en
ti
ﬁ
ed
C
en
tr
a
l
B
C
D
ec
ea
se
d
S
T
C
7
4
A
4
5
G
8
2
F
F
ij
ia
n
S
ep
ti
c
a
rt
h
ri
ti
s
n
.a
.
C
en
tr
a
l
B
C
&
jo
in
t
a
sp
ir
a
te
D
ec
ea
se
d
1
2
.8
4
6
C
3
1
F
F
ij
ia
n
A
b
sc
es
s
n
.a
.
C
en
tr
a
l
B
C
R
ec
o
v
er
ed
n
.a
.
4
7
C
5
7
F
F
ij
ia
n
S
ep
si
s
D
ia
b
et
es
C
en
tr
a
l
B
C
R
ec
o
v
er
ed
S
T
C
7
4
A
4
8
C
7
5
M
F
ij
ia
n
P
n
eu
m
o
n
ia
n
.a
.
N
o
rt
h
er
n
B
C
R
ec
o
v
er
ed
n
.a
.
4
9
C
7
7
M
F
ij
ia
n
S
ep
ti
c
a
rt
h
ri
ti
s
N
o
ri
sk
fa
ct
o
r
id
en
ti
ﬁ
ed
C
en
tr
a
l
B
C
R
ec
o
v
er
ed
S
T
C
5
3
4
5
n
.a
.,
In
fo
rm
a
ti
o
n
n
o
t
a
v
a
il
a
b
le
;
B
C
,
b
lo
o
d
cu
lt
u
re
.
*
P
y
o
d
er
m
a
re
p
o
rt
ed
in
p
re
ce
d
in
g
2
8
d
a
y
s.
Invasive streptococcal infections in Fiji 625
Australia and possibly in other developing nations in
tropical and subtropical regions.
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